Pharma: Other News To Note
Monday, June 4, 2012
Ranbaxy Laboratories Inc., of Princeton, N.J., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., is planning to launch Absorica (isotretinoin) in the fourth quarter, now that the FDA has approved the drug for the treatment of severe recalcitrant nodular acne. Absorica is partnered with Mississauga, Ontario-based Cipher Pharmaceuticals Inc., which will receive royalties on net sales.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.